Indeed, the combination of neoplastic PD-L1 expression with immunosenescence/immunodeficiencies in a host appears to predict shorter progression-free survival, which is exemplified by PD-L1-expressing MTX-associated CHL-type LPD [136,142]. Here, CD274 is linked to immune system disorder.